MPR Weekly Dose

MPR Weekly Dose

Each week the MPR team brings you the top stories from the world of medicine and pharma in a matter of minutes. With 35 years of publishing drug information behind us, you can rely on MPR to provide accurate and up-to-date news.

Denne podkasten er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(275)

MPR Weekly Dose 76 - Bamlanivimab emergency use changes; Janssen vaccine facilities; Molnupiravir trial halted; New contraceptive approved; Ragweed pollen allergy treatment

MPR Weekly Dose 76 - Bamlanivimab emergency use changes; Janssen vaccine facilities; Molnupiravir trial halted; New contraceptive approved; Ragweed pollen allergy treatment

The FDA revoke Emergency Use Authorization for bamlanivimab; Issues identified at a Janssen manufacturing facility; Merck halts trials for investigational COVID-19 therapy; A new contraceptive is appr...

23 Apr 202113min

MPR Weekly Dose 75 - Janssen vaccine on pause; Antibody therapy guidance; Remote mifepristone dispensing; Xolair self-administration; And a new AI colonoscopy system

MPR Weekly Dose 75 - Janssen vaccine on pause; Antibody therapy guidance; Remote mifepristone dispensing; Xolair self-administration; And a new AI colonoscopy system

The latest status on the Janssen vaccine; Updated guidance from the National Institutes of Health on COVID-19 antibody treatments; The FDA changes in-person mifepristone dispensing; Xolair prefilled s...

16 Apr 202111min

MPR Weekly Dose 74 - Updated travel guidance; Six month vaccine efficacy data; Increased Moderna doses per vial; New ADHD treatment; And a safety communication for lamotrigine

MPR Weekly Dose 74 - Updated travel guidance; Six month vaccine efficacy data; Increased Moderna doses per vial; New ADHD treatment; And a safety communication for lamotrigine

Back to regular programming this week with a summary of the top news, which includes updated travel guidance; Six month efficacy data for the Moderna and Pfizer-BioNTech vaccines; Vial doses increased...

9 Apr 202111min

MPR Weekly Dose #73: Interview with Dr Joshua Barocas

MPR Weekly Dose #73: Interview with Dr Joshua Barocas

With three FDA authorized vaccines being administered throughout the US, but new variants growing in number, we are at a crucial moment in the COVID-19 pandemic.  To get a better understanding of ho...

30 Mar 202123min

MPR Weekly Dose 72 - Real world vaccine effectiveness; Two-dose completion data; Moderana pediatric trial; Results from tocilizumab plus remdesivir trial; Kimyrsa approved.

MPR Weekly Dose 72 - Real world vaccine effectiveness; Two-dose completion data; Moderana pediatric trial; Results from tocilizumab plus remdesivir trial; Kimyrsa approved.

This week we have new study data on the real-world effectiveness of the Pfizer-BioNTech vaccine; The number of Americans who are completing both vaccine doses; A vaccine trial that has started in chil...

18 Mar 202110min

MPR Weekly Dose 71 - Guidance for those fully vaccinated; A first in COVID-19 testing; Povidone Iodine and Bamlanivimab-Etesevimab examined; Delayed local vaccine reactions

MPR Weekly Dose 71 - Guidance for those fully vaccinated; A first in COVID-19 testing; Povidone Iodine and Bamlanivimab-Etesevimab examined; Delayed local vaccine reactions

This week it's all COVID related news; There's new CDC guidance for those who are vaccinated; A first over the counter test that doesn't require a prescription; Nasopharyngeal povidone iodine and the ...

12 Mar 202110min

MPR Weekly Dose 70 - Keytruda indication withdrawn; Janssen's single-shot vaccine gains EUA; Ivermectin assessed for mild COVID-19; FDA clears wearables

MPR Weekly Dose 70 - Keytruda indication withdrawn; Janssen's single-shot vaccine gains EUA; Ivermectin assessed for mild COVID-19; FDA clears wearables

This week we have news of an indication for the cancer treatment, Keytruda, being withdrawn; Janssen's single dose vaccine gains Emergency Authorization; There's findings on the effectiveness of Iverm...

5 Mar 202111min

MPR Weekly Dose #69 - False and misleading pharma promo; Novel LDL-C therapy; Heart failure Tx expanded; Migraine device okay'd for teens.

MPR Weekly Dose #69 - False and misleading pharma promo; Novel LDL-C therapy; Heart failure Tx expanded; Migraine device okay'd for teens.

An FDA warning over pharma company's promo material; Entresto's approval is expanded, There's approvals in homozygous familial hypercholesterolemia and chronic inflammatory demyelinating polyneuropath...

18 Feb 202111min

Populært innen Helse

fastlegen
rss-gukild-johaug
lydartikler-fra-aftenposten
psykodrama
hvordan-har-du-det-mann
leger-om-livet
relasjonspodden-med-dora-thorhallsdottir-kjersti-idem
foreldreradet
rss-garne-damer
bak-fasaden-en-reise-i-livet-med-sykepleier-ine
rss-skravla-gar
klimaks
morten-ramm-lar-kakla-ga-til-du-sovner
rss-lopedrommen
hjernesterk
g-punktet
sinnsyn
hverdagspsyken
rss-kunsten-a-leve
apent-forhold